Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecuritySVA / Sinovac Biotech Ltd. (P8696W104)
Institutional Owners31
Institutional Shares17,876,295
Institutional Value$ 136,433,000 USD

Institutional Stock Ownership and Shareholders()

SVA / Sinovac Biotech Ltd. Institutional Ownership

Sinovac Biotech Ltd. (NASDAQ:SVA) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17,876,295 shares. Largest shareholders include SAIF Advisors Ltd, Orbimed Advisors Llc, Renaissance Technologies LLC, Neumann Advisory Hong Kong Ltd, GLG Partners LP, Deutsche Bank Ag\, Eqis Capital Management, Inc., State Street Corp, Invesco Ltd., and California Public Employees Retirement System.
Sinovac Biotech Ltd. (NASDAQ:SVA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/sva"><img src="https://images.fintel.io/us-sva-so.png" alt="SVA / Sinovac Biotech Ltd. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-04 13F-HR Financial Gravity Companies, Inc. 10,546 135 -98.72 87 1 -98.85
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 35,232 46,685 32.51 278 402 44.60
2018-05-15 13F-HR STATE STREET CORP 88,254 136,169 54.29 695 1,172 68.63
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 300 0 -100.00 2 0 -100.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 27,490 1,432 -94.79 217 12 -94.47
2018-05-15 13F-HR Wellington Management Group LLP 69,098 0 -100.00 544 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 62,000 92,127 48.59 489 793 62.17
2018-05-15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 13,200 10,000 -24.24 104 86 -17.31
2018-05-15 13F-HR ORBIMED ADVISORS LLC 2,839,500 2,839,500 0.00 22,375 24,448 9.26
2018-05-14 13F-HR MORGAN STANLEY 23,851 2,280 -90.44 188 20 -89.36
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 21,899 20,840 -4.84 173 179 3.47
2018-04-06 13F-HR Eqis Capital Management, Inc. 156,492 158,993 1.60 1,233 1,369 11.03
2018-05-15 13F-HR TWO SIGMA INVESTMENTS LLC 52,473 18,302 -65.12 413 158 -61.74
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 33,600 0 -100.00 265 0 -100.00
2018-05-10 13F-HR Spark Investment Management LLC 66,100 66,100 0.00 520 569 9.42
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 27,717 27,717 0.00 218 238 9.17
2018-05-14 13F-HR DLD Asset Management, LP 13,200 10,000 -24.24 104 86 -17.31
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 0 20 0 0
2018-05-11 13F-HR SEI INVESTMENTS CO 17 0 -100.00 0 0
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 64 65 1.56 5 7 40.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 25,100 28,500 13.55 198 245 23.74
2017-10-26 13F-HR Acrospire Investment Management LLC 5,030 0 -100.00 34 0 -100.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 26,300 0 -100.00 207 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 24,400 22,300 -8.61 192 192 0.00
2018-05-15 13F-HR PIONEER INVESTMENT MANAGEMENT INC 8,100 8,300 2.47 64 71 10.94
2018-05-15 13F-HR DEUTSCHE BANK AG\ 245,328 178,466 -27.25 1,933 1,536 -20.54
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 46,400 48,400 4.31 366 417 13.93
2018-04-26 13F-HR CWM, LLC 500 500 0.00 4 4 0.00
2018-05-15 13F-HR UBS Group AG 0 7,616 0 66
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1,250 1,250 0.00 10 11 10.00
2018-05-09 13F-HR IFP Advisors, Inc 2,000 2,000 0.00 16 17 6.25
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 28,500 245
2018-05-14 13F-HR Renaissance Technologies LLC 2,687,400 2,639,500 -1.78 21,177 22,726 7.31
2018-05-23 13F-HR Financial Gravity Wealth, Inc. 135 1
2018-05-15 13F-HR CREDIT SUISSE AG/ 20,700 0 -100.00 163 0 -100.00
2017-10-18 13F-HR SAIF Advisors Ltd 10,780,820 10,780,820 0.00 72,771 76,005 4.44
2018-02-14 13F-HR GLG Partners LP 758,859 271,072 -64.28 5,342 2,136 -60.01
2018-05-03 13F-HR SG Americas Securities, LLC 23,241 24,021 3.36 183 207 13.11
2018-04-26 13F-HR SIMPLEX TRADING, LLC 274 0 -100.00 2 0 -100.00
2018-05-15 13F-HR Invesco Ltd. 0 107,171 0 923
2018-07-12 13F-HR Neumann Advisory Hong Kong Ltd 402,844 402,844 0.00 3,469 3,005 -13.38

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

6h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Week In Review: Suzhou Innovent Files For HK IPO - $500 Million Raise Rumored

2018-07-08 seekingalpha
Innovent Biologics of Suzhou has filed to IPO on the Hong Kong Exchange under its new rules for pre-revenue biopharmas. The company plans to raise as much as $500 million, according to media reports, at a valuation of over $1 billion. Founded in 2011, Innovent has developed a pipeline of 17 biologic drugs with an emphasis on oncology. In 2015, the company formed a historic partnership with Lilly (NYSE: LLY) worth up to $1 billion plus. (16-0)

10 Little-Known Stocks That Could Be Huge | InvestorPlace

2018-05-18 investorplace
The 10-year U.S. Treasury has crossed the rubicon. It is now flashing a yield that is over the 3% mark. What befalls the economy when that happens? Recession? Correction? A grinding bear market? (6-2)

BRIEF-Sinovac Resumes Production And Operation At Its Beijing's Quality Assurance Department

2018-04-23 reuters
* SINOVAC BIOTECH LTD - HEPATITIS A VACCINE AND SEASONAL FLU VACCINE PRODUCTION HAS RESUMED AT SHANGDI MANUFACTURING FACILITY OF UNIT (5-1)

10 Healthcare Stocks to Stave Off the Market Flu

2018-04-06 investorplace
While the markets run up and down because tech stocks are doing one thing or another, or retailers struggle to improve same-store sales, there isn’t much debate about the future of the healthcare sector. (173-1)

BRIEF-Sinovac Enters Into Amendment To Amalgamation Agreement For Going-Private Transaction

2018-03-27 reuters
* SINOVAC BIOTECH LTD - AMENDMENT EXTENDS TERMINATION DATE TO APRIL 26, 2018 FOR THE AMALGAMATION AGREEMENT DATED AS OF JUNE 26, 2017 Source text for Eikon: Further company coverage: ([email protected]) (5-1)

CUSIP: P8696W104